High non-protective, long-lasting antibody levels in malaria are associated with haplotype shifting in MHC-peptide-TCR complex formation: a new mechanism for immune evasion

Biochimie

Volumn 88, Issue 7, 2006, Pages 775-784

  Patarroyo, Manuel E ^a,b   Bermúdez, Adriana ^a   Salazar, Luz Mary ^a,b   Espejo, Fabiola ^a  

^a FUNDACIÓN INSTITUTO DE INMUNOLOGÍA DE COLOMBIA FIDIC   (Colombia)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

Author keywords

Immunogenic peptides; Long lasting antibody; Malaria vaccine; MHC II peptide TCR Complex

Indexed keywords

ANTIBODY; HLA DR ANTIGEN; PEPTIDE DERIVATIVE; T LYMPHOCYTE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; AOTUS; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; HAPLOTYPE; IMMUNE RESPONSE; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALARIA; NONHUMAN; PLASMODIUM FALCIPARUM; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, PROTOZOAN; AOTIDAE; BLOTTING, WESTERN; COMPUTER SIMULATION; HLA-DR ANTIGENS; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; MALARIA; MALARIA VACCINES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDES; PLASMODIUM FALCIPARUM; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, ANTIGEN, T-CELL; SEQUENCE HOMOLOGY, AMINO ACID;

PLASMODIUM FALCIPARUM;

EID: 33746520045     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2006.01.005     Document Type: Article

References (39)

1. Greenwood B., and Mutabingwa T. Malaria in 2002. Nature 415 (2002) 670-672
2. Patarroyo M.E., Amador R., Clavijo P., Moreno A., Guzmán F., Romero P., Tascon R., Franco A., Murillo L.A., and Ponton G. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature 328 (1987) 629-632
3. Patarroyo M.E., Amador R., Clavijo P., Moreno A., Guzmán F., Romero P., Tascon R., Franco A., Murillo L.A., and Ponton G. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 332 (1988) 158-161
4. Amador R., Moreno A., Murillo L.A., Sierra O., Saavedra D., Rojas M., Mora A.L., Rocha C.L., Alvarado F., and Falla J.C. Safety and immunogenicity of the synthetic malaria vaccine SPf66 in a large field trial. J. Infect. Dis. 166 (1992) 139-144
5. Valero M.V., Amador R., Galindo C., Figueroa J., Bello M.S., Murillo L.A., Mora A.L., Patarroyo G., Rocha C., and Rojas M. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Lancet 341 (1993) 705-710
6. Noya O., Gabaldon-Berti Y., Alarcon de Noya B., Borges R., Zerpa N., Urbaez J.D., Madonna A., Garrido E., Jimenez M.A., and Borges R.E. A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela. J. Infect. Dis. 170 (1994) 396-402
7. Sempertegui F., Estrella B., Moscoso J., Piedrahita L., Hernandez D., Gaybor J., Naranjo P., Mancero O., Arias S., and Bernal R. Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador. Vaccine 12 (1994) 337-342
8. Alonso P.L., Smith T., Schellenberg J.R., Masanja H., Mwankusye S., Urassa H., Bastos de Azevedo I., Chongela J., Kobero S., and Menendez C. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 344 (1994) 1175-1181
9. Valero M.V., Amador R., Aponte J.J., Narvaez A., Galindo C., Silva Y., Rosas J., Guzmán F., and Patarroyo M.E. Evaluation of Spf66 malaria vaccine during a 22 month follow-up field trial in the Pacific coast of Colombia. Vaccine 14 (1996) 1466-1470
10. Acosta C.J., Galindo C.M., Schellenberg D., Aponte J.J., Kahigwa E., Urassa H., Schellenberg J.R., Masanja H., Hayes R., and Kitua A.Y. Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania. Trop. Med. Int. Health 4 (1999) 368-376
11. Nosten F., Luxemburger C., Kyle D.E., Ballou W.R., Wittes J., Wah E., Chongsuphajaisiddhi T., Gordon D.M., White N.J., Sadoff J.C., and Heppner D.G. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in north-western Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. Lancet 348 (1996) 701-707
12. Urquiza M., Rodriguez L.E., Suarez J.E., Guzman F., Ocampo M., Curtidor H., Segura C., Trujillo E., and Patarroyo M.E. Identification of Plasmodium falciparum MSP-1 peptides able to bind to human red blood cells. Parasite Immunol. 18 (1996) 515-526
13. Murillo L.A., Rocha C.L., Mora A.L., Kalil J., Goldenberg A.K., and Patarroyo M.E. Molecular analysis of HLA DR4-ß1 gene in malaria vaccinees. Typing and Subtyping by PCR technique and oligonucleotides. Parasite Immunol. 13 (1991) 201-210
14. Niño-Vasquez J.J., Vogel D., Rodríguez R., Moreno A., Patarroyo M.E., Pluschke G., and Daubenberger C.A. Sequence and diversity of DRB genes of Aotus nancymaae, a primate model for human malaria parasites. Immunogenetics 51 (2000) 219-230
15. Alba M.P., Salazar L.M., Vargas L.E., Trujillo M., López Y., and Patarroyo M.E. Modifying RESA protein peptide 6671 to fit into HLA-DRbeta1* pockets induces protection against malaria. Biochem. Biophys. Res. Commun. 315 (2004) 1154-1164
16. Cubillos M., Salazar L.M., Torres L., and Patarroyo M.E. Protection against experimental P. falciparum malaria is associated with short AMA-1 peptide analogue α-helical structures. Biochimie 84 (2003) 1181-1188
17. Salazar L.M., Alba M.P., Torres M.H., Pinto M., Cortes X., Torres L., and Patarroyo M.E. Protection against experimental malaria associated with AMA-1 peptide analogue structures. FEBS Lett. 527 (2002) 95-100
18. Purmova J., Salazar L.M., Espejo F., Torres M.H., Cubillos M., Torres E., López Y., Rodríguez R., and Patarroyo M.E. NMR structure of Plasmodium falciparum malaria peptide correlates with protective immunity. Biochim. Biophys. Acta 1571 (2002) 27-33
19. Torres M.H., Salazar L.M., Vanegas M., Guzmán F., Rodríguez R., Silva Y., Rosas J., and Patarroyo M.E. Modified merozoite surface protein-1 peptides with short alpha helical regions are associated with inducing protection against malaria. Eur. J. Biochem. 270 (2003) 3946-3952
20. Salazar L.M., Alba M.P., Curtidor H., Bermúdez A., Vargas L.E., Rivera Z.J., and Patarroyo M.E. Changing ABRA protein peptide to fit into the HLA-DRbeta1*0301 molecule renders it protection-inducing. Biochem. Biophys. Res. Commun. 322 (2004) 119-125
21. Cifuentes G., Espejo F., Vargas L.E., Parra C., Vanegas M., and Patarroyo M.E. Orientating peptide residues and increasing the distance between pockets to enable fitting into MHC-TCR complex determine protection against malaria. Biochemistry 43 (2004) 6545-6553
22. Patarroyo M.E., Alba M.P., Vargas L.E., Silva Y., Rosas J., and Rodriguez R. Peptides inducing short-lived antibody responses against Plasmodium falciparum malaria have shorter structures and are read in a different MHC II functional register. Biochemistry 44 (2005) 6745-6754
23. Sinigaglia F., Romagnoli P., Guttinger M., Takacs B., and Pink J.R. Selection of T cell epitopes and vaccine engineering. Methods Enzymol. 203 (1991) 370-386
24. Marsh S.G., Parham P., and Barber L.D. The HLA Facts Book (2000), Academic Press, New York 358-363
25. Houghten R.A. General method for the rapid solid phase synthesis of large numbers of peptides: specificity of antigen antibody interaction at the level of individual amino acids. Proc. Natl. Acad. Sci. USA 82 (1985) 5131-5135
26. Rodriguez R., Moreno A., Guzman F., Calvo M., and Patarroyo M.E. Studies in owl monkeys leading to the development of a synthetic vaccine against the asexual blood stages of Plasmodium falciparum. Am. J. Trop. Med. Hyg. 43 (1990) 339-354
27. Blake M.S., Johnston K.H., Russell-Jones G.J., and Gotschlich E.C. A rapid, sensitive method for detection of alkaline phosphatase-conjugated anti-antibody on Western blots. Anal. Biochem. 136 (1984) 175-179
28. Rammensee H.G., Friede T., and Stevanoviic S. MHC ligands and peptide motifs: first listing. Immunogenetics 41 (1995) 178-228
29. Dessen A., Lawrence C.M., Cupo S., Zaller D.M., and Wiley D.C. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 7 (1997) 473-481
30. Nwuba R.I., Sodeinde O., Anumudu C.I., Omosun Y.O., Odaibo A.B., Holder A.A., and Nwagwu M. The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies. Infect. Immun. 70 (2002) 5328-5331
31. Morgan W.D., Frenkiel T.A., Lock M.J., Grainger M., and Holder A.A. Precise epitope mapping of malaria parasite inhibitory antibodies by TROSY NMR cross-saturation. Biochemistry 44 (2005) 518-523
32. Dutta S., Haynes J.D., Moch J.K., Barbosa A., and Lanar D.E. Invasion-inhibitory antibodies inhibit proteolytic processing of apical membrane antigen 1 of Plasmodium falciparum merozoites. Proc. Natl. Acad. Sci. USA 100 (2003) 12295-12300
33. Healer J., Murphy V., Hodder A.N., Masciantonio R., Gemmill A.W., Anders R.F., Cowman A.F., and Batchelor A. Allelic polymorphisms in apical membrane antigen-1are responsible for evasion of antibody-mediated inhibition in Plasmodium falciparum. Mol. Microbiol. 52 (2004) 159-168
34. Hennecke J., and Wiley D.C. Structure of a complex of the human alpha/beta T cell receptor (TCR) HA1.7, influenza hemagglutinin peptide, and major histocompatibility complex class II molecule, HLA-DR4 (DRA*0101 and DRB1*0401): insight into TCR cross-restriction and alloreactivity. J. Exp. Med. 195 (2002) 571-581
35. Kersh G.J., Miley M.J., Nelson C.A., Grakoui A., Horvath S., Donermeyer D.L., Kappler J., Allen P.M., and Fremont D.H. Structural and functional consequences of altering a peptide MHC anchor residue. J. Immunol. 166 (2001) 3345-3354
36. Wu L.C., Tuot D.S., Lyons D.S., Garcia K.C., and Davis M.M. Two-step binding mechanism for T-cell receptor recognition of peptide MHC. Nature 418 (2002) 552-556
37. Coppel R.L., Cowman A.F., Anders R.F., Bianco A.E., Saint R.B., Lingelbach K.R., Kemp D.J., and Brown G.V. Immune sera recognize on erythrocytes Plasmodium falciparum antigen composed of repeated amino acid sequences. Nature 310 (1984) 789-792
38. Quakyi I.A., Currier J., Fell A., Taylor D.W., Roberts T., Houghten R.A., England R.D., Berzofsky J.A., Miller L.H., and Good M.F. Analysis of human T cell clones specific for conserved peptide sequences within malaria proteins. Paucity of clones responsive to intact parasites. J. Immunol. 153 (1994) 2082-2092
39. Saul A. The role of variant surface antigens on malaria-infected red blood cells. Parasitol. Today 15 (1999) 455-457